Forte Biosciences Soars 42.63% on Positive Celiac Disease Study

On June 23, 2025, Forte Biosciences rose 42.63% in pre-market trading, marking a significant surge in its stock price.

Forte Biosciences recently announced positive data from its FB102 Celiac Disease Phase 1B study. The study demonstrated a statistically significant benefit on the composite histological VCIEL endpoint, indicating a meaningful change from baseline. This positive outcome has generated considerable interest and optimism among investors, contributing to the stock's pre-market surge.

The company's announcement highlighted the potential of FB102 in treating celiac disease, a condition that affects millions of people worldwide. The positive data from the Phase 1B study suggests that FB102 could be a promising therapeutic option, addressing a significant unmet medical need. This development has bolstered investor confidence in Forte Biosciences' pipeline and its ability to deliver innovative treatments.

Forte Biosciences' positive data release has not only driven its stock price higher but also underscored the company's commitment to advancing its clinical programs. The successful Phase 1B study results position Forte Biosciences well for future development and potential regulatory approvals, further enhancing its market position in the biotechnology sector.